Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events - Test2 - elhamkhani - TriplyDB

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events

http://www.wikidata.org/entity/Q28195656

about

A randomised controlled trial of triple antiplatelet therapy (aspirin, clopidogrel and dipyridamole) in the secondary prevention of stroke: safety, tolerability and feasibility The effect of preoperative treatment of P2Y12 receptor antagonists on perioperative bleeding and mortality in patients treated with coronary artery bypass grafting (CABG)The effect of preoperative treatment of P2Y12 receptor antagonists on perioperative bleeding and mortality in patients treated with coronary artery bypass grafting (CABG)Multiple versus one or more antiplatelet agents for preventing early recurrence after ischaemic stroke or transient ischaemic attack Adenosine-diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2 diabetes mellitus Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke Epidemiology, classification, and modifiable risk factors of peripheral arterial disease Platelet function and ageing Current status of high on-treatment platelet reactivity in patients with coronary or peripheral arterial disease: Mechanisms, evaluation and clinical implications Should dual antiplatelet therapy be used in patients following coronary artery bypass surgery? A meta-analysis of randomized controlled trials Coming safely to a stop: a review of platelet activity after cessation of antiplatelet drugs TIA Management: Should TIA Patients be Admitted? Should TIA Patients Get Combination Antiplatelet Therapy?Clopidogrel and Aspirin versus Aspirin Alone for Stroke Prevention: A Meta-Analysis Current perspectives in NSAID-induced gastropathy Treatment and prevention of gastrointestinal bleeding in patients receiving antiplatelet therapy Effect of addition of clopidogrel to aspirin on mortality: systematic review of randomized trials Biomarkers for stroke Limb salvage in women Lost in translation: what have we learned from the CHARISMA trial?Clopidogrel in ST-elevation myocardial infarction patients undergoing percutaneous coronary intervention Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study Aspirin and clopidogrel resistance: consideration and management Antithrombotic treatment for peripheral arterial disease The safety and efficacy of aspirin and clopidogrel as a combination treatment in patients with coronary heart disease My health: whose responsibility? Low-dose aspirin and older people Prasugrel Evolving perspectives on clopidogrel in the treatment of ischemic stroke Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease Pharmacological interventions for peripheral artery disease Clopidogrel: an updated and comprehensive review Risk reduction with clopidogrel in the management of peripheral arterial disease Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patient Anithrombotic prevention in vascular disease: bases for a new strategy in antithrombotic therapy Pharmacological prevention of atherothrombotic events in patients with peripheral arterial disease Contemporary issues in clopidogrel therapy: new evidence shaping clinical practice Hypersensitivity of platelets to adenosine diphosphate in patients with stable cardiovascular disease predicts major adverse events despite antiplatelet therapy The PRoFESS trial: future impact on secondary stroke prevention

P2860

Q21144269-148E130F-7C0B-4876-96CA-08AB23C45036 Q24187718-070215B2-5DCB-4695-83DB-3891746B07D1 Q24197708-7D581857-643A-4EC0-9B0C-BDCD362C6A3E Q24201386-5BDCA05C-E4EE-47AB-AE5E-9605911E478F Q24203035-EE26F34A-2F25-4C55-9FA1-9A8382976ED0 Q24234632-9775C03B-3409-4ACB-8884-E6DD20D1EB2F Q24243939-AA8B253D-ADEC-46C0-A117-1002AFAF2B69 Q24244298-D1930FE4-7882-47F2-BDF2-EE508230D114 Q24646522-BBE489B6-1735-48E5-9D1F-6F71DB3C2FA5 Q24681271-6DE64834-FCEE-4E25-95AF-86B4018C2457 Q26749231-84DB9C35-8663-469A-90CA-F8DDDECE5EC9 Q26771106-EEA7D97B-8278-485F-A1B2-9FC1EC9B97A7 Q26782970-E1B59DA1-FAA1-4F43-8509-6909A9AB7F13 Q26795403-D2298367-B910-4D85-9328-D2643E4438E0 Q26796466-0EA01426-7330-4ADA-878E-E932C7F0CEF7 Q26798213-39BB9FFB-2613-4A24-9948-336CC20426A0 Q26827673-C99C61D1-B6E0-4F4C-AA37-2E9CEDC41C25 Q26866350-1C5203C3-AF0C-436E-BB11-B714F3A38AED Q26999848-D3003278-56F5-4899-92F3-A96D0B721EE8 Q27004404-B71CFA4A-B32F-4579-B7B4-5FA019FBC501 Q27010121-74766E36-11DA-4127-99F4-55323924A4DB Q28199586-24829CE4-E7DA-4AEC-90EF-12E75D1203FE Q28199817-388D0642-1988-48BC-80CF-18E37323E29F Q28200506-949CF965-7F0D-4F42-950E-9C29790DE559 Q28200610-CE5E4088-627B-49F0-A60C-B073FA38020F Q28200650-74A3D48B-D73D-4A53-BD08-CAD200F5AA92 Q28200757-05936EA7-C131-4252-B558-FD112AA34622 Q28201631-DF439EA2-79A2-4050-8B9B-F17A7AD3E235 Q28210429-CC04008D-2F4D-4CFC-86A1-5A0C946FB074 Q28217627-50013450-D00B-41F8-B15D-0C1F2F50CECA Q28218124-BF716097-BBC5-40DC-A3A6-A954B1A781D4 Q28218976-9CB48999-0BB1-4303-B353-D730E5F8A74E Q28219411-DF72E1AF-B353-44D8-8945-5031F61C13B0 Q28219578-DD26B751-C976-498D-8DC5-F704EED75B5E Q28219951-58541C3D-A95F-4CC2-9B69-9E42855A3672 Q28220433-D294AA7B-4A21-46B0-B8B7-E7FCC4E80A0C Q28220999-62527C5B-E513-4DA9-BBFE-89F036A4CD5E Q28221366-F9DE1795-9484-4154-B88C-5D5456BAAB49 Q28221437-054BD0E8-C3A6-4826-A371-F8BAC82F5EE3 Q28221589-D2664298-1A05-463F-A22F-180464EB8F12

P2860

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events

http://www.wikidata.org/entity/Q28195656

description

2006 nî lūn-bûn

@nan

2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Clopidogrel and aspirin versus ...... ion of atherothrombotic events

@ast

Clopidogrel and aspirin versus ...... ion of atherothrombotic events

@en

Clopidogrel and aspirin versus ...... ion of atherothrombotic events

@nl

type

label

Clopidogrel and aspirin versus ...... ion of atherothrombotic events

@ast

Clopidogrel and aspirin versus ...... ion of atherothrombotic events

@en

Clopidogrel and aspirin versus ...... ion of atherothrombotic events

@nl

prefLabel

Clopidogrel and aspirin versus ...... ion of atherothrombotic events

@ast

Clopidogrel and aspirin versus ...... ion of atherothrombotic events

@en

Clopidogrel and aspirin versus ...... ion of atherothrombotic events

@nl

P1433

Q28195656-6AE79ED6-3D50-479D-AF2B-E7DF238007D9

P1476

Q28195656-46DB568C-4682-488A-B991-586B72FFC55C

P2093

Q28195656-052EB555-0323-471F-9A68-18BA24D39528

Q28195656-09028D61-3D23-446C-9A29-6904982A9135

Q28195656-175EE018-073D-4B4D-8B84-994D0082E73B

Q28195656-60D399BA-FA1D-471A-A2C8-B68FE47ACEF2

Q28195656-72AA9E39-4141-47DC-A77D-2314AC8442B8

Q28195656-9AE131C2-D122-4D52-BDC4-1C5345E42F3C

Q28195656-A20E526F-F0AB-40D6-B7F1-EFB9CB647932

Q28195656-A5B66872-0291-483D-876F-EF4A374BA26B

Q28195656-B47CA42E-BA68-469D-A4FB-EB627799AD34

Q28195656-BBA9DF1E-4D3C-43D7-9F0C-B9F4A2D9758B

P304

Q28195656-22D2A86C-2719-449E-82CC-D8038FDFEECC

P31

Q28195656-F77440B1-37E3-4BE7-8CAA-D5659AD61DC1

P3181

Q28195656-DCCA2F0D-2C75-4774-9EED-C4FC51FAADCF

P356

Q28195656-2DAB0EDF-D877-4C69-8763-6A5F2FB98F7D

P407

Q28195656-9E491455-53A4-44EA-B2C2-777CC7F7C148

P433

Q28195656-D865B6DB-59A9-4C56-8908-CADFD0BEE7CD

P478

Q28195656-7F15DF85-64FB-46D3-9D33-262D01D4A005

P50

Q28195656-4B0721BC-5967-4C0A-ACBD-B24E5C1E4DEB

Q28195656-5405C9B9-25A9-42BB-BEE9-09881B39C46E

Q28195656-54A34DB6-5292-4E44-BE61-6F99925178ED

Q28195656-88484169-44D0-4E56-99FA-15BB584A5D61

Q28195656-93D99B2E-5F0D-4A13-9F54-7BCF5FD60882

Q28195656-C02D66C0-2171-4AAC-9DD6-9FD1C6A78BE6

Q28195656-DBF07FA6-95C4-424C-9FFA-BF73967BB9A0

Q28195656-E7D946BC-AC09-45DC-B7FA-ADD49F0F36B8

P577

Q28195656-56A2EE9C-5F6D-41F1-B6B3-260B5AA819A9

P698

Q28195656-51F38ACC-8987-4CA3-B6B6-44FA942581F8

P921

Q28195656-9A4E2190-F567-4C3D-98A3-E0D359498BD2

Q28195656-BBF3B860-90D3-4EF9-8052-503414E0049D

P3181

P356

P1433

The New England Journal of Medicine

P1476

Clopidogrel and aspirin versus ...... ion of atherothrombotic events

@en

P2093

Christian W Hamm

http://www.w3.org/2001/XMLSchema#string

Eric A Cohen

http://www.w3.org/2001/XMLSchema#string

Henry R Black

http://www.w3.org/2001/XMLSchema#string

J Donald Easton

http://www.w3.org/2001/XMLSchema#string

Jean-Louis Mas

http://www.w3.org/2001/XMLSchema#string

Joan Booth

http://www.w3.org/2001/XMLSchema#string

Keith A A Fox

http://www.w3.org/2001/XMLSchema#string

Koon-Hou Mak

http://www.w3.org/2001/XMLSchema#string

Liz Fabry-Ribaudo

http://www.w3.org/2001/XMLSchema#string

Marcus D Flather

http://www.w3.org/2001/XMLSchema#string

P304

1706-17

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

925229

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA060989

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

354

http://www.w3.org/2001/XMLSchema#string

P50

Gilles Montalescot

Graeme J. Hankey

Deepak L. Bhatt

Steven R Steinhubl

Danielle M Brennan

Peter B. Berger

P577

2006-04-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16531616

http://www.w3.org/2001/XMLSchema#string

P921